Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab for Clearance of Detectable Minimal Residual Disease in Chronic Lymphocytic Leukemia
NCT07052695Phase 2
Key facts
- Status
- Recruiting
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Countries
- 1
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Drugs
- mosunetuzumab
- Conditions
- chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
01
Overview
Phase 2, open-label trial of mosunetuzumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms). Primary endpoint: Rate of undetectable bone marrow minimal residual disease at 1 year. Started Nov 2025; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
BCL2i arm
Mosunetuzumab monotherapy for patients previously treated with BCL2i
BTKi arm
Mosunetuzumab + continuous BTKi for patients already on BTKi
03
Who it enrols
Adults with CLL or SLL with detectable MRD (>=10e-4) who are either on continuous BTKi therapy for >12 months or completed BCL2i-based therapy <12 months prior. Must have adequate organ function and ECOG <= 2.
04
Endpoints
Primary
Rate of undetectable bone marrow minimal residual disease
Secondary
Safety of mosunetuzumab
Efficacy of mosunetuzumab
Beyond the preview
Go deeper on NCT07052695.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052695.